Skip to content
Antibodies & Bispecifics
Antibody Platforms
Monoclonal Discovery
Bispecific Discovery
Optimization
TCR Mimics
Genetic Medicines
Partnering
Ecosystem Allies
About
Leadership
News and Events
Careers
Resources
Antibodies & Bispecifics
Antibody Platforms
Monoclonal Discovery
Bispecific Discovery
Optimization
TCR Mimics
Genetic Medicines
Partnering
Ecosystem Allies
About
Leadership
News and Events
Careers
Resources
Contact Us
Full resource library
Alloy Therapeutics resources all in one place
Modality
Solution
Type
Modality
Antibodies and Bispecifics
Genetic Medicines
TCR Mimics
Solution
Antibody Platforms
Bispecific Discovery
Monoclonal Discovery
Optimization
TCR Mimic
Type
Case Studies
Perspectives
Press Releases
Technical Notes
Webinars
Technical Notes
Highly Specific anti-WT1/HLA-A2 TCRm Antibodies
Learn more
Press Releases
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
Learn more
Press Releases
Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies
Learn more
Case Studies
Discovery of highly-specific TCR mimic antibodies to WT1
Learn more
Webinars
Daedamab High Velocity Antibody Discovery
Learn more
Press Releases
Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service
Learn more
Press Releases
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
Learn more
Webinars
Keyway TCRm Discovery Webinar
Learn more
Webinars
Discovering Antibodies in Months
Learn more
